Connecticut biotech Halda Therapeutics, created by Arvinas founder Craig Crews, has reeled in another $126 million to start clinical testing of its oral molecules for …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
During my 25 years working in clinical trial operations, I’ve seen the biopharmaceutical world talk a big game about making the process easier for the
AMSTERDAM — Novel anti-amyloid agent acoramidis improved a composite of outcome endpoints in the pivotal ATTRibute-CM trial for transthyretin mediated amyloidosis (ATTR) cardiomyopathy, with suggestion
Middle-aged adults with three or more unhealthy traits including slightly high waist circumference, blood pressure, cholesterol and glucose have heart attacks and strokes two years